Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing-remitting Multiple Sclerosis (RRMS)”

183 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 183 results

Large-scale testing (Phase 3)Study completedNCT01707992
What this trial is testing

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 2,199
Large-scale testing (Phase 3)Study completedNCT03774407
What this trial is testing

Vaginal Estriol in Multiple Sclerosis

Who this might be right for
Multiple SclerosisNeurogenic Bladder
Texas Tech University Health Sciences Center 21
Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Not applicableStudy completedNCT00787657
What this trial is testing

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Bayer 1,723
Testing effectiveness (Phase 2)Study completedNCT00882999
What this trial is testing

Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Eli Lilly and Company 245
Testing effectiveness (Phase 2)Study completedNCT02782858
What this trial is testing

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GeNeuro SA 270
Not applicableStudy completedNCT01456416
What this trial is testing

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Southern California 10
Testing effectiveness (Phase 2)Study completedNCT00676715
What this trial is testing

The Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 220
Post-approval studies (Phase 4)Ended earlyNCT03126760
What this trial is testing

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Mallinckrodt ARD LLC 35
Post-approval studies (Phase 4)Study completedNCT02019550
What this trial is testing

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
EMD Serono 97
Post-approval studies (Phase 4)Study completedNCT01705236
What this trial is testing

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Who this might be right for
Relapsing Remitting Multiple Sclerosis RRMS
Novartis Pharmaceuticals 87
Post-approval studies (Phase 4)Study completedNCT01578330
What this trial is testing

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Who this might be right for
Multiple SclerosisRelapsing-Remitting
Novartis Pharmaceuticals 42
Large-scale testing (Phase 3)Study completedNCT00360906
What this trial is testing

Omega-3 Fatty Acid Treatment in Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Haukeland University Hospital 100
Early research (Phase 1)Study completedNCT01884935
What this trial is testing

PK and PD Study of Natalizumab in Pediatric Subjects With RRMS

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 13
Post-approval studies (Phase 4)WithdrawnNCT02675413
What this trial is testing

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Washington University School of Medicine
Large-scale testing (Phase 3)Study completedNCT04115488
What this trial is testing

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Polpharma Biologics S.A. 265
Not applicableLooking for participantsNCT07292480
What this trial is testing

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Centre Hospitalier Universitaire de Nīmes 84
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07503340
What this trial is testing

Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Hoffmann-La Roche 25
Early research (Phase 1)Ended earlyNCT01318421
What this trial is testing

ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 12
Not applicableActive Not RecruitingNCT03983681
What this trial is testing

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

Who this might be right for
Multiple Sclerosis
Kessler Foundation 120
Load More Results